TrueNorth Advises Kobayashi on Acquisition of Focus Consumer Healthcare

October 17, 2023 TrueNorth News

Stamford, CT, October 2023: TrueNorth Capital Partners LLC is pleased to announce that its wholly-owned subsidiary, TNCP, LLC (“TrueNorth”) acted as exclusive financial advisor to Kobayashi Pharmaceutical Co., Ltd, (TYO 4967) (“Kobayashi”) on its acquisition of 100% ownership in Focus Consumer Healthcare, LLC (“Focus”) through its wholly-owned subsidiary Kobayashi Healthcare International Inc. (“KHI”).


Focus sells niche brands comprising supplements and OTC medicines, including garlic supplements, period and cold sore relief medicines, sold at brick-and mortar stores and through e-commerce throughout the United States. Focus is based in Chattanooga, Tennessee.

The acquisition of Focus will allow Kobayashi to establish its presence in the supplement market and expand their OTC business in North America. Kobayashi intends to generate synergies by combining garlic-specific and women’s medicine brands with the group’s functional materials, prescription expertise, and marketing capabilities

Mr. Koji Akita, President and CEO of Kobayashi Healthcare International Inc., stated that, “We are very excited about this opportunity for us to expand our consumer healthcare business in US.”

Mr. Daniel Yim, President of Kobayashi Consumer Products also commented, “TrueNorth’s assistance was invaluable as we navigated all the challenges of this auction process, and I am excited to work with the Focus team to bring out the synergies between the two groups.”

Tsuyoshi (Yoshi) Togo, Managing Director at TrueNorth, with assistance from Fred Rossetti and Matt Kodama, acted as Lead Bankers on this transaction with further support by Ani Vajjah, Vice President, and Hong Phung, Analyst.

Any further inquiries can be directed to TrueNorth at the contact information provided below:

Yoshi Togo, Managing Director
Direct Dial Phone Number: (203) 817-0284
E-mail address:

Fred Rossetti, Managing Director
Direct Dial Phone Number: (203) 817-0276
E-mail address:

About Kobayashi Pharmaceutical Co., Ltd:

Kobayashi (TYO 4967) together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, household products, skincare, and body warmers. Additionally, the company manufactures and sells pharmaceuticals, quasi-drugs, cosmetics, hygiene and paper products, health foods, and processed synthetic resin products, markets nutritional supplements and skin care products through the website and over the phone, and sells skincare products, daily necessities, and health foods. Further, it engages in transportation, real estate management, advertising planning and production businesses, and asset management. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.

About Focus Consumer Healthcare:

Focus Consumer Healthcare is leading consumer healthcare products company that markets and sells a portfolio of OTC medicines and supplements brands, including garlic supplements, period and cold sore relief medicines, at brick-and mortar stores and through e-commerce throughout the United States. Its major brands include GARLIQUE, PAMPRIN and HERPECIN L. Focus is based in Chattanooga, Tennessee.

About TrueNorth Capital Partners LLC:

TrueNorth provides advisory services to companies seeking advice for middle-market M&A and financing transactions. With offices in Stamford CT, Charleston SC, Central NJ, Minneapolis MN, Tokyo Japan, and London UK, TrueNorth is a boutique investment bank comprised of senior bankers providing a full complement of financial advisory services. Our focus on the middle-market enables us to provide independent, value-added advisory services to privately held middle-market companies, private equity and family office groups and corporate clients, both domestic and international, across a broad range of industries. TrueNorth conducts its securities related business through its wholly owned subsidiary, TNCP, LLC, member FINRA/SIPC.